This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peterson, E. D. Search for Related Content PubMed PubMed Citation Articles by Peterson, E. D.

From controlled trials to clinical practice

monitoring transmyocardial revascularization use and outcomes

Eric D. Peterson, MD, MPH, FACC^*,*, Padma Kaul, PhD^*, Ronald G. Kaczmarek, MD, Bradley G. Hammill, BA, MS^*, Paul W. Armstrong, MD, FACC, Charles R. Bridges, MD, ScD, FACC, T. Bruce Ferguson, Jr, MD^|| Society of Thoracic Surgeons

^* Duke Clinical Research Institute, Durham, North Carolina, USA
University of Alberta, Edmonton, Canada
Food and Drug Administration, Rockville, Maryland, USA
University of Pennsylvania, Philadelphia, Pennsylvania, USA
^|| Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA

View larger version (20K): [in a new window]   Figure 1 Thirty-day transmyocardial revascularization (TMR) mortality rates from clinical trials and from the Society of Thoracic Surgeons (STS) registry database. An overall combined rate (assuming random effects) of clinical trials results is provided for descriptive purposes only. CABG = coronary artery bypass graft surgery; RCT = randomized clinical trial.

View larger version (23K): [in a new window]   Figure 2 Independent predictors of operative mortality following transmyocardial revascularization (TMR) from the Society of Thoracic Surgeons (STS) database. CABG = coronary artery bypass graft surgery; CI = confidence interval; EF = ejection fraction; MI = myocardial infarction; OR = odds ratio; PVD = peripheral vascular disease.